The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Oxazole derivatives-based cancer drug compositions. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Oxazole derivatives-based cancer drug compositions is a key innovation area in the pharmaceutical industry
Oxazoles, which have oxygen and nitrogen atoms present within their core structure, enable interactions with different enzymes and receptors. Oxazole derivatives possess potent anticancer activity by inhibiting targets such as STAT3 and G-quadruplex. They also inhibit tubulin protein to induce apoptosis in cancer cells. Other targets such as DNA topoisomerase enzyme, protein kinases, and miscellaneous targets including Cdc25, mitochondrial enzymes, HDAC, LSD1, HPV E2 TAD, NQO1, aromatase, BCl-6, estrogen receptor, GRP-78, and Keap-Nrf2 pathway are inhibited by oxazole derivatives.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of oxazole derivatives-based cancer drug compositions.
Key players in oxazole derivatives-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to oxazole derivatives-based cancer drug compositions
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|F. Hoffmann-La Roche||195||Unlock Company Profile|
|Vertex Pharmaceuticals||160||Unlock Company Profile|
|Arbutus Biopharma||100||Unlock Company Profile|
|HEC Pharm Group||91||Unlock Company Profile|
|Pfizer||72||Unlock Company Profile|
|Betta Pharmaceuticals||56||Unlock Company Profile|
|Kirin Holdings||53||Unlock Company Profile|
|Alnylam Pharmaceuticals||49||Unlock Company Profile|
|Johnson & Johnson||43||Unlock Company Profile|
|Orion Holdings||40||Unlock Company Profile|
|AbbVie||38||Unlock Company Profile|
|C. H. Boehringer Sohn||37||Unlock Company Profile|
|Jiangsu Hengrui Medicine||35||Unlock Company Profile|
|Beijing Scitech-MQ Pharmaceuticals||34||Unlock Company Profile|
|Daiichi Sankyo||34||Unlock Company Profile|
|BioMarin Pharmaceutical||28||Unlock Company Profile|
|Cancer Research UK||27||Unlock Company Profile|
|E. Merck||27||Unlock Company Profile|
|Pierre Fabre Foundation||27||Unlock Company Profile|
|Incyte||24||Unlock Company Profile|
|Bayer||23||Unlock Company Profile|
|Triphase Accelerator||22||Unlock Company Profile|
|Bristol-Myers Squibb||22||Unlock Company Profile|
|Teva Pharmaceutical Industries||21||Unlock Company Profile|
|Actuate Therapeutics||20||Unlock Company Profile|
|PIQUR Therapeutics||19||Unlock Company Profile|
|Capella Therapeutics||19||Unlock Company Profile|
|Zydus Lifesciences||19||Unlock Company Profile|
|Zhejiang Beta Pharma||19||Unlock Company Profile|
|Forma Therapeutics Holdings||18||Unlock Company Profile|
|Capulus Therapeutics||18||Unlock Company Profile|
|TransThera Sciences (Nanjing)||16||Unlock Company Profile|
|IRM||16||Unlock Company Profile|
|Raze Therapeutics||15||Unlock Company Profile|
|Cancer Research Technology||15||Unlock Company Profile|
|TaiRx||15||Unlock Company Profile|
|Capgemini||15||Unlock Company Profile|
|Beta Pharma||14||Unlock Company Profile|
|Infinity Pharmaceuticals||13||Unlock Company Profile|
|ExonHit Therapeutics||13||Unlock Company Profile|
|Innate Pharma||12||Unlock Company Profile|
|Hanmi Science||11||Unlock Company Profile|
|Merck & Co||11||Unlock Company Profile|
|Mitsubishi Chemical Group||11||Unlock Company Profile|
|Gvk Davix Technologies Pvt.||11||Unlock Company Profile|
|Strides Pharma Science||11||Unlock Company Profile|
|Sumitomo Chemical||11||Unlock Company Profile|
|Eli Lilly and||9||Unlock Company Profile|
|Araxes Pharma||9||Unlock Company Profile|
|North & South Brother Pharmacy Investment||9||Unlock Company Profile|
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche is the leading patent filer of oxazole derivatives-based cancer drug compositions. The company develops drugs and diagnostics to treat major diseases. Its product range includes medicines for the treatment of cancer, auto-immune diseases, central nervous system diseases, ophthalmological disorders, infectious diseases, and respiratory diseases. Vertex Pharmaceuticals and Arbutus Biopharma are the other key patent filers of oxazole derivatives-based cancer drug compositions.
In terms of application diversity, Alnylam Pharmaceuticals is the top company, followed by Arbutus Biopharma and Forma Therapeutics. By means of geographic reach, Alnylam Pharmaceuticals also holds the top position. Whilst C. H. Boehringer Sohn and Teva Pharmaceutical Industries stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.